Safety of Statin and Fibrate Combination Therapy

Evidence Supporting Safety

The American Heart Association recommends combination therapy with fenofibrate and any statin when clinically indicated, with fenofibrate being the preferred fibrate for statin-fibrate combination therapy 1
The FIELD study found no cases of rhabdomyolysis in approximately 1,000 patients receiving statin-fenofibrate combination therapy 1
The ACCORD study demonstrated no statistically significant differences in the incidence of myositis, rhabdomyolysis, or hepatic transaminase elevations with simvastatin-fenofibrate combination therapy compared to simvastatin monotherapy in patients with type 2 diabetes 1
FDA Adverse Event Reporting System data show that rhabdomyolysis reports per 1 million prescriptions were approximately 15 times lower for fenofibrate than for gemfibrozil when prescribed with statins 1

The American College of Cardiology and American Heart Association guideline states that fenofibrate may be considered concomitantly with a low- or moderate-intensity statin only if the benefits from ASCVD risk reduction or triglyceride lowering outweigh the potential risk for adverse effects 2
Patients with mixed dyslipidemia requiring both LDL-C reduction and triglyceride lowering may benefit from this combination 1, 2
Patients with triglycerides ≥500 mg/dL at risk for pancreatitis may benefit from this combination 2, 3

Renal status must be evaluated before fenofibrate initiation, within 3 months after initiation, and every 6 months thereafter using both serum creatinine and eGFR, as recommended by the American College of Cardiology 2
Fenofibrate should not be used if eGFR <30 mL/min per 1.73 m², and the dose should not exceed 54 mg/day if eGFR is 30-59 mL/min per 1.73 m² 2
Baseline creatine kinase (CK) should be obtained before initiating combination therapy, and patients should be educated to report muscle symptoms, as recommended by the American Heart Association 1
Hepatic transaminases should be monitored approximately 12 weeks after starting therapy, then annually or more frequently if indicated, as recommended by the American College of Cardiology 2

Fenofibrate is associated with increases in serum creatinine, which is typically reversible upon discontinuation but requires monitoring, as noted by the American College of Cardiology 4, 2
The ACCORD trial showed that fenofibrate-simvastatin did not reduce cardiovascular events compared to simvastatin alone in the overall trial population or in those with or without clinical CVD, but patients with triglycerides ≥204 mg/dL and HDL-C ≥40 mg/dL may have experienced cardiovascular benefit, according to the American College of Cardiology 4